Evotec SE
ISIN: DE0005664809
WKN: 566480
06 November 2024 07:00AM

EQS-News: Evotec SE reports 9M 2024 results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions

Evotec SE · ISIN: DE0005664809 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 2023203

EQS-News: Evotec SE / Key word(s): 9 Month figures
Evotec SE reports 9M 2024 results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions

06.11.2024 / 07:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


  • Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditions
  • Robust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnerships 
  • Successful extensions & expansions with BMS and Novo Nordisk; new collaboration with Pfizer to advance cutting-edge therapeutic solutions
  • Priority reset on track to deliver annualised adj. EBITDA improvement of over € 40 m and strategic review initiated


Hamburg, Germany, 06 November 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced its financial results and corporate updates for the third quarter of 2024, highlighting strategic progress across key partnerships and operations.

Dr Christian Wojczewski, Chief Executive Officer of Evotec, said: “We continue to deliver on the successful execution of our Priority Reset and have achieved significant progress across key initiatives. New and extended partnerships clearly underscore Evotec’s enduring leadership in R&D and precision medicine. Building on this exceptionally strong foundation, we are now laying the groundwork for an accelerated transformation program that will pave the way for long-term profitable growth. While the challenging market environment has impacted near-term results, we are seeing strong momentum across strategic priorities and look forward to reporting back on our progress in early 2025.”
 

Challenging market conditions weigh on Shared R&D, while Just – Evotec Biologics delivers strong growth

  • Group revenues decreased by (1)% to € 575.7 m (9M 2023: € 580.1 m)
  • Total Shared R&D revenues decreased by (12)% to € 447.1 m (9M 2023: € 506.1 m, due to a challenging market environment
  • Evotec’s Just – Evotec Biologics segment saw impressive growth, with revenues rising by 74% year-over-year, contributing €128.7 m (9M 2023: € 74.1 m) to the overall topline
  • Adjusted Group EBITDA totalled € (6.0) m (9M 2023: € 50.2 m) driven by a mismatch between revenues and cost base in the Shared R&D segment as well as costs related to the expansion of operations of Just – Evotec Biologics
  • Core business activities in Shared R&D as well as Just – Evotec Biologics reached break-even
     

Transformation Process on track with significant savings realised

  • Priority Reset is set to yield an annualised adjusted EBITDA improvement of over € 40 m, starting H2 2024
  • Successful implementation of measures to improve liquidity
  • One-off costs related to Priority Reset measures recognised at € 62.3 m as of Q3, lower than initial provision of € 68.5 m on 30 June 2024
  • Strategic Review process initiated to examine status quo and deliver performance and productivity improvements as part of transformation for long-term profitable growth

New and expanded partnerships

  • Extension and expansion of tech partnership with Sandoz for development and commercial manufacturing of biosimilars
  • Extension of collaboration with Bristol Myers Squibb (“BMS”) based on targeted protein degradation into indications outside of oncology, triggering programme-based payment of US$ 50 m to fund further research
  • Further progress made in strategic neuroscience collaboration with Bristol Myers Squibb, payments of US$ 25 m received
  • Strong progress in strategic protein degradation partnership with Bristol Myers Squibb, resulted in reception of performance-based and programme-based payments of in total US$ 75 m
  • New technology development partnership with Novo Nordisk to support next-generation cell therapies
  • New multi-year master research collaboration and option and license agreement with Pfizer, initially focusing on early discovery research for metabolic and infectious diseases
  • Collaboration with X-Chem to access DNA-encoded library (“DEL”) to expand hit-finding options

Operational milestone achieved

  • Opening of cutting-edge biologics facility J.POD in Toulouse, France (EU) on 20 September 2024 marks significant expansion of European production capabilities and strengthens position in the biologics market.

Business Outlook for full-year 2024

  • Group revenues1) expected in the range of € 790 – 820 m (2023: € 781.4 m).
  • R&D expenditures are expected in a range of € 50 – 60 m (2023: € 64.8 m).
  • Adjusted Group EBITDA1) is expected to reach € 15 – 35 m (2023: € 66.4 m).

1) Guidance including future non-core activities 

More detailed information and financial tables are available in the half-year report published on the Evotec website under the following link: https://www.evotec.com/en/investor-relations/financial-publications

 

Webcast/Conference Call

The Company plans to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.


Webcast details

Date:  Wednesday, 06 November 2024

Time:  2.00 pm CET (01.00 pm BT, 08.00 am ET)

To join the audio webcast and to access the presentation slides, please register via this link.

The on-demand version of the webcast will be available on our website: www.evotec.com/en/investor-relations/financial-publications.


Conference call details

To join via phone, please pre-register via this link.

You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.

A simultaneous slide presentation for participants dialling in via phone is available under this link.

 

About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company’s sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.

Forward-looking-statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

 

For further information, please contact:

Investor Relations

Volker Braun
EVP Head of Global Investor Relations & ESG
volker.braun@evotec.com


Media

Susanne Kreuter
VP Head of Strategic Marketing

susanne.kreuter@evotec.com



06.11.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: SDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 2023203

 
End of News EQS News Service

2023203  06.11.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2023203&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 375,41 446,44 500,92 618,03 751,45 781,43 895,00
EBITDA1,2 95,46 123,14 51,77 101,65 102,51 66,35 140,00
EBITDA-Margin3 25,43 27,58 10,34 16,45 13,64 8,49 15,64
EBIT1,4 77,46 62,59 48,52 41,00 20,85 -47,51 30,00
EBIT-Margin5 20,63 14,02 9,69 6,63 2,78 -6,08 3,35
Net Profit (Loss)1 84,06 37,23 6,25 215,51 -175,66 -83,91 17,00
Net-Margin6 22,39 8,34 1,25 34,87 -23,38 -10,74 1,90
Cashflow1,7 156,24 42,22 44,72 122,24 203,11 36,44 0,00
Earnings per share8 0,46 0,25 0,04 1,30 -0,99 -0,47 0,11
Dividend per share8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: BDO

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Evotec
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
566480 DE0005664809 SE 1.492,34 Mio € 10.11.1999 Halten 9F5FMXGW+WH
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
15,86 35,60 0,45 72,46 1,54 40,95 1,91
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
0,00 0,00 0,00 0,00%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
10.06.2024 07.05.2025 13.08.2025 06.11.2024 17.04.2025
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
+1,08%
8,41 €
ATH 102,50 €
+9,11% -3,44% -60,50% -60,07% -35,35%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL